Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496483 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients
A Phase 2 study, sponsored by Veloxis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00496483: Completed Phase 2 study, sponsored by Veloxis Pharmaceuticals.
NCT00496483 is a Phase 2 study that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496483, a Phase 2 study, has completed, sponsored by Veloxis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
A three sequence, open-label, multi-center, prospective, study in stable kidney transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
Primary Outcome
Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.
Interventions
- DRUG Prograf
- DRUG LCP Tacro (tacrolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
What the finished NCT00496483 record still lists
NCT00496483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Prograf is the first listed.
NCT00496483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00496483 about?
NCT00496483 is a clinical study titled "Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients". A three sequence, open-label, multi-center, prospective, study in stable kidney transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
What is the current status of trial NCT00496483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-07. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00496483?
The interventions under investigation include: Prograf (DRUG), LCP Tacro (tacrolimus) (DRUG).
Who is sponsoring clinical trial NCT00496483?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00496483's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia